Achillion Pharmaceuticals, Inc

Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease - HIV, hepatitis and resistant bacterial infections. The Company's lead candidate is elvucitabine, a novel nucleoside analog currently being evaluated in Phase 2 studies for the treatment of patients with HIV. Achillion believes that elvucitabine addresses several of the limitations of currently marketed therapies and is an ideal candidate for partnerships around combination preparations and/or geographic commercialization alliances. Achillion is also developing ACH-702, its candidate for the treatment of serious, hospital-based bacterial infections, and multiple NS4A antagonists, a unique class of candidates for the treatment of hepatitis C, which are partnered with Gilead Sciences. Both ACH-702 and the NS4A antagonists were discovered through Achillion's own proprietary internal drug discovery efforts. Achillion sees significant competitive advanges in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing...